Sanofi & GSK to support COVAX with 200 m adjuvanted recombinant protein-based COVID-19 vaccines
Sanofi and GSK plan to make available to the Gavi lead COVAX Facility 200 million doses of their adjuvanted recombinant
Read moreSanofi and GSK plan to make available to the Gavi lead COVAX Facility 200 million doses of their adjuvanted recombinant
Read moreEli Lilly and Company officially announced on Oct. 28, an initial deal with the U.S. government to supply 300,000 vials
Read moreAmerican biotech Moderna has signed an agreement with the Ministry of Public Health to supply Qatar with its mRNA COVID-19
Read moreAstraZeneca has confirmed that the U.S. FDA has authorised the resumption of Phase III clinical trials of the COVID-19 AZD1222
Read moreSYNLAB, leading European provider of medical diagnostic solutions, has revealed the successful authorization of saliva sampling platform, another groundbreaking non-invasive
Read moreThis year, more than ever has required the pharma industry to dive into digitalisation in all shapes and forms. With
Read moreViiV Healthcare’s GEMINI studies showed that the 2-drug regimen (2DR) of dolutegravir plus lamivudine, appeared to have non-inferior potency in
Read moreEnzolytics, Inc, a drug development company with a focus on debilitating infectious diseases, announced on September 16, the execution of
Read moreUnited States President Donald Trump has been administered with an intravenous dose of Regeneron Pharmaceuticals experimental COVID-19 treatment REGN-COV2, a
Read moreThe range of clinical responses to SARS-CoV-2 infection is extremely broad, a factor making the disease particularly difficult to properly
Read more